A Phase 1 interventional study of RGT-490 in Breast Cancer, Ovarian Cancer and Endometrial Cancer, sponsored by Regor Pharmaceuticals Inc.. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Regor Pharmaceuticals Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors including breast cancer.
Participants enrolled in the study have advanced disease that is not amendable to curative treatment and whose tumors harbor alterations in the PI3KCA gene.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
This study's planned enrollment of 63 is below the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Regor Pharmaceuticals Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RGT-490 given alone as monotherapy
Drug: RGT-490
RGT-490 given alone as monotherapy
Drug: RGT-490
Oral tablets
Incidence of dose limiting toxicities (DLTs)
Number of subjects who experience at least 1 Dose Limiting Toxicity (DLT)
Time frame: 4 weeks (1 cycle)
Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) and AEs leading to dose modifications and dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
Time frame: Every cycle (4-week cycles) until study discontinuation, approximately 12 months
Characterize the Cmax (PK) of RGT-490 monotherapy in Dose Escalation
Maximum observed plasma concentration (Cmax) of RGT-490
Time frame: First 3 treatment cycles (each cycle is 28 days)
Characterize the Tmax (PK) of RGT-490 monotherapy in Dose Escalation
Maximum observed plasma concentration (Tmax) of RGT-490
Time frame: First 3 treatment cycles (each cycle is 28 days)
Characterize the AUC (PK) of RGT-490 monotherapy in Dose Escalation
Calculated area under the plasma concentration curve (AUC) of RGT-490
Time frame: First 3 treatment cycles (each cycle is 28 days)
Measure PD effects of RGT-490 monotherapy in Dose Escalation and Phase 1b
Change from baseline in ctDNA levels; Change from baseline in PD markers in paired biopsies
Time frame: First 7 cycles (each cycle is 28 days) and at study discontinuation
Changes in fasting blood glucose
Measured by fasting blood glucose
Time frame: Approximately every week in Cycle 1 and Cycle 2 (4-week cycle), every 2 weeks in Cycles 3-6 (4-week cycle), and every cycle through end of treatment (4-week cycles), approximately 24 months
Changes in longitudinal glucose metabolism (All Phases)
Measured by HbA1c
Time frame: Approximately every cycle (4-week cycles) until study discontinuation, approximately 24 months
Assess preliminary efficacy of RGT-490 monotherapy in dose escalation and Phase 1b
Objective response rate (ORR) based on RECIST v1.1
Time frame: Approximately every 8 weeks until progressive disease, approximately 12 months
Evaluate additional measures of efficacy of RGT-490
Duration of response (DoR) according to RECIST v1.1
Time frame: Approximately every 8 weeks until progressive disease, approximately 36 months
Evaluate additional measures of efficacy of RGT-490
Progression free survival (PFS) according to RECIST v1.1
Time frame: Approximately every 8 weeks until progressive disease, approximately 36 months
Started Jul 2026 (actual). Primary completion is estimated for Apr 2028, 21 months after the start.
Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 21 months is below that.
Counting every sponsor, half of 762 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2026, on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Regor Pharmaceuticals Inc.